Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579683 · ClinicalTrials.gov registry record
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 228
- Enrollment target
NCT00579683: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00579683 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 228 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00579683 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 228 participants
- Enrollment target
Study Summary
The purpose of this study is to try to learn more about how small molecule kinase inhibitors work in treating lung cancer. Some early studies have shown that gefitinib, erlotinib and similar drugs are more likely to work if a particular DNA change (also known as a mutation) is found in a protein that is important in lung cancer. This protein is called the epidermal growth factor receptor (EGFR). Since small molecule kinase inhibitors sometimes stop working, we would like to examine your tumor to learn why these medicines are not working as well. Your tumor will be examined for a variety of things including changes in the DNA of the EGFR. We will also sequence parts of the genes for HER2, HER3, HER4, and KRAS, other proteins thought to be important in lung cancer.
Interventions
- OTHER Tumor core biopsy for RNA isolation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2004-08 |
| Est. Completion | 2016-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579683
The ClinicalTrials.gov registry entry for NCT00579683 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor core biopsy for RNA isolation is the first listed.
NCT00579683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579683 about?
NCT00579683 is a clinical study titled "Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer". The purpose of this study is to try to learn more about how small molecule kinase inhibitors work in treating lung cancer. Some early studies have shown that gefitinib, erlotinib and similar drugs are more likely to work if a particular DNA change (also known as a mutation) is found in a protein tha...
What is the current status of trial NCT00579683?
This trial is currently completed. The enrollment target is 228 participants. The study started on 2004-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00579683?
The interventions under investigation include: Tumor core biopsy for RNA isolation (OTHER).
Who is sponsoring clinical trial NCT00579683?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.